🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

DENTSPLY SIRONA Inc. XRAY R3KPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.dentsplysirona.com
Company Profile ↓
$10.14
-25.08% 1Y
Mkt Cap$2.03B
P/E-3.50
P/B1.84
Div. Yield5.04%
52W High$14.68
52W Low$9.64
Book Value$6.58
EPS (TTM)$-2.90

Company Overview

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.

Why Investors Should Care

Dividend Income

Offers a dividend yield of 5.04%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $3.68B (-3.0% YoY); net profit $-598.00M.
  • Trailing 12 Months Year-on-year growth — revenue +0.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.62%
1 Year:0.10%

Stock Price Performance

1 Year:-25.08%
6 Months:-17.02%
3 Months:-2.97%
1 Month:-9.38%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 10% of range
$9.64 $14.68
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)35.35 · Neutral
Price Performance
1M-9.38%
3M-2.97%
6M-17.02%
1Y-25.08%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Attractive dividend yield of 5.04%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 30.9% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.50
Industry PE
24.25
Forward P/E
6.62
PEG Ratio
0.75
Book Value
$6.58
Price to Book
1.84
P/S
0.66
EV/EBITDA
8.62
Dividend Yield
5.04%

Growth (CAGR)

Revenue 5Y
3.62%
Profit 5Y
-
Revenue (YoY)
0.10%
Earnings (YoY)
-

Profitability & Returns

ROCE
6.17%
ROE
-37.67%
ROA
2.26%
Profit Margin
-17.06%
Op Margin
3.41%
Gross Margin
48.93%
EPS (Latest Qtr)
$0.18
EPS (TTM)
$-2.90

Balance Sheet & Liquidity

Debt/Equity
1.78
Quick Ratio
0.67
Current Ratio
1.53
Debt
$2.34B
Total Assets
$5.20B
Current Assets
$1.84B
Working Capital
$680.00M

Ownership

Promoter Holding
0.65%
Chg in Prom Hold
0.02%
FII / Inst Holding
117.21%
Chg in FII Hold
0.11%

Financial Snapshot

Enterprise Value
$2.03B
Total Revenue (TTM)
$3.68B
EBITDA
$556.00M
Free Cash Flow
$129.62M
Operating Cash Flow
$268.00M
Shares Outstanding
200.33M
Gross Margin
48.93%
Payout Ratio
28.83%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 XRAY DENTSPLY SIRONA Inc. R3KPHARMA 10.14 -3.50 $2.03B 5.04% 6.17% -37.67% 3.62% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,137.82 38.18 $1.01T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 267.28 31.04 $644.12B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 263.04 74.52 $464.82B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 144.91 115.93 $357.90B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 375.26 24.13 $336.83B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 138.70 20.98 $263.63B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.89 24.42 $252.62B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 648.43 34.94 $239.76B 0.32% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----------956.10M1.04B928.40M1.06B946.20M1.01B962.10M1.11B874.00M491.00M895.00M1.03B1.06B1.04B969.00M1.02B947.00M978.00M1.03B947.00M953.00M984.00M951.00M-879.00M936.00M904.00M961.00M880.00M898.00M
Cost of Revenue ----------------------------------413.00M446.00M463.00M518.00M453.00M-
Gross Profit 369.40M374.70M418.90M526.90M513.60M541.50M492.00M544.20M559.00M593.30M514.10M552.80M476.10M524.80M499.70M540.80M514.00M610.60M468.00M176.00M442.00M579.00M595.00M569.00M521.00M581.00M508.00M519.00M550.00M495.00M506.00M511.00M495.00M-466.00M490.00M441.00M443.00M427.00M493.00M
Operating Expenses ----------------------------------396.00M380.00M395.00M418.00M397.00M-
Operating Income 98.60M93.10M72.70M121.20M126.60M134.20M84.20M-1.05B107.90M-706.40M68.70M-1.15B45.50M81.80M47.30M67.50M109.50M136.60M-125.00M-104.00M82.00M150.00M154.00M132.00M97.00M119.00M-1.22B-2.00M80.00M-236.00M42.00M50.00M-462.00M-70.00M110.00M46.00M25.00M30.00M82.00M
EBITDA ----------------------------------142.00M-41.00M-115.00M-32.00M61.00M-
Interest Expense ----------------------------------19.00M24.00M23.00M22.00M24.00M-
Pretax Income ----------------------------------44.00M-153.00M-230.00M-147.00M-42.00M-
Tax Provision ----------------------------------25.00M-109.00M198.00M-2.00M-32.00M-
Net Income 84.50M58.60M125.00M105.40M92.50M107.00M59.70M-1.05B90.60M-650.40M81.20M-1.12B28.00M1.80M39.20M36.40M85.00M102.30M-140.00M-95.00M53.00M112.00M96.00M84.00M69.00M73.00M-1.08B-19.00M86.00M-266.00M18.00M-4.00M-494.00M-20.00M-45.00M-427.00M-146.00M-10.00M37.00M
Diluted EPS 0.590.410.700.440.390.460.26-4.580.35-2.850.35-4.980.130.010.170.160.380.46-0.63-0.440.250.510.430.380.320.34-5.01-0.090.40-1.250.09-0.02-2.46-0.10-0.22-2.14-0.74-0.050.18
R&D Expense ------------------34.00M18.00M27.00M40.00M43.00M39.00M45.00M45.00M41.00M46.00M49.00M46.00M42.00M41.00M40.00M-36.00M37.00M37.00M-44.00M45.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.01B2.19B2.16B2.22B2.54B2.93B00003.99B3.99B4.03B3.34B-3.92B3.96B3.79B3.68B
Cost of Revenue ---------------1.79B1.88B1.83B1.84B
Gross Profit 1.04B1.15B1.11B1.13B1.27B1.56B1.58B1.60B1.52B2.00B2.19B2.07B2.17B1.66B-2.13B2.09B1.96B1.84B
Operating Expenses ---------------1.76B1.80B1.77B1.59B
Operating Income 354.89M380.46M381.24M380.27M300.73M381.94M419.20M445.60M375.20M454.70M-1.56B-958.00M361.00M-3.00M-364.00M289.00M188.00M252.00M
EBITDA ----------------662.00M249.00M-518.00M-46.00M
Interest Expense ---------------65.00M81.00M69.00M88.00M
Pretax Income ----------------1.05B-175.00M-936.00M-486.00M
Tax Provision ----------------105.00M-43.00M-26.00M112.00M
Net Income 259.65M283.87M274.26M265.71M244.52M314.21M313.20M322.90M251.20M429.90M-1.55B-1.01B263.00M-73.00M--950.00M-132.00M-910.00M-598.00M
Diluted EPS 1.681.871.831.821.702.182.162.241.761.94-6.76-4.511.17-0.33--4.41-0.62-4.48-3.00
R&D Expense -48.50M50.30M66.70M85.40M85.40M85.10M80.80M74.90M128.50M151.70M161.00M143.00M123.00M171.00M174.00M184.00M165.00M150.00M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --2.83B3.09B3.26B4.76B4.97B5.08B4.65B4.40B11.56B10.37B8.69B8.60B9.34B-7.64B7.37B5.75B5.43B
Current Assets ----------------1.89B1.97B1.75B2.02B
Cash & Equivalents 65.06M169.38M203.99M450.35M540.04M77.13M80.10M75.00M151.60M284.60M383.90M320.60M309.60M405.00M438.00M-365.00M334.00M272.00M326.00M
Inventory ----------------627.00M624.00M564.00M642.00M
Receivables ----------------632.00M695.00M556.00M688.00M
Total Liabilities --1.17B1.18B1.35B2.87B2.72B2.50B2.32B2.06B3.43B3.75B3.55B3.51B4.37B-3.83B4.08B3.81B4.09B
Current Liabilities --359.96M444.56M360.09M724.07M927.78M796.40M652.60M476.00M767.60M954.50M1.01B995.00M1.32B-1.17B1.43B1.59B1.34B
Long Term Debt --423.68M387.15M604.01M1.49B1.22B1.17B1.15B1.14B1.51B1.61B1.56B1.43B1.98B-1.83B1.80B1.59B2.02B
Total Debt ----------------2.15B2.30B2.27B2.47B
Total Equity 1.27B1.52B1.59B1.83B1.84B1.85B2.21B2.54B2.32B2.34B8.11B6.62B5.12B5.09B4.97B-3.81B3.29B1.94B1.34B
Shares Outstanding ----------------264.60M264.50M264.50M264.50M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 387.70M335.98M362.49M377.46M393.47M369.69M417.80M560.40M497.40M563.40M601.90M500.00M633.00M649.00M-517.00M377.00M461.00M235.00M
Investing Cash Flow -299.39M-47.80M-53.40M-164.47M-1.89B-115.02M-260.20M-138.70M-54.90M60.00M-286.40M-253.00M-69.00M-1.11B--138.00M-89.00M-197.00M-132.00M
Financing Cash Flow 3.21M-229.09M-71.42M-103.04M1.00B-255.61M-161.70M-336.20M-302.90M-526.20M-400.80M-250.00M-466.00M476.00M--329.00M-307.00M-302.00M-80.00M
Capital Expenditure -----------144.30M-183.00M-123.00M-87.00M--149.00M-149.00M-180.00M-131.00M
Free Cash Flow ----------457.60M317.00M510.00M562.00M-368.00M228.00M281.00M104.00M
Net Change in Cash ---------------50.00M-19.00M-38.00M23.00M
Share Buybacks -112.63M78.72M223.99M79.50M38.84M118.00M163.20M112.70M813.90M401.40M250.00M260.00M140.00M200.00M150.00M300.00M250.00M0
Dividends Paid 25.13M26.95M29.84M29.08M28.63M31.43M34.80M37.30M40.00M64.60M78.30M79.00M81.00M88.00M92.00M104.00M116.00M126.00M128.00M

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 51.8%52.4%51.2%50.9%50.2%53.1%----54.8%51.9%53.7%49.6%-54.2%52.6%51.6%50.0%
Operating Margin % 17.7%17.4%17.7%17.1%11.9%13.0%-----39.1%-24.0%9.0%-0.1%-9.3%7.3%5.0%6.8%
Net Margin % 12.9%13.0%12.7%12.0%9.6%10.7%-----38.8%-25.4%6.5%-2.2%--24.2%-3.3%-24.0%-16.2%
ROE % 17.1%17.9%15.0%14.4%13.2%14.2%12.4%13.9%10.7%5.3%-23.4%-19.7%5.2%-1.5%--24.9%-4.0%-46.9%-44.7%
ROCE % -15.4%14.4%13.1%7.5%9.4%9.8%11.2%9.6%4.2%-16.6%-12.5%4.7%-0.0%-5.6%4.9%4.5%6.2%

Shareholding Pattern

Insiders
0.65%
Institutions
117.21%
Public Float
117.97%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 13.40% 26.71M $297.03M
2 Fuller & Thaler Asset Management Inc. 6.37% 12.70M $141.19M
3 Vanguard Portfolio Management LLC 5.91% 11.78M $130.99M
4 AQR Capital Management, LLC 5.25% 10.46M $116.30M
5 State Street Corporation 4.66% 9.29M $103.25M
6 Vanguard Capital Management LLC 4.54% 9.05M $100.61M
7 Lazard Asset Management LLC 4.15% 8.27M $91.96M
8 Ariel Investments, LLC 4.03% 8.03M $89.25M
9 Southpoint Capital Advisors Lp 3.51% 7.00M $77.84M
10 Cooke & Bieler LP 3.48% 6.93M $77.04M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XRAY

Yahoo Finance ue, 08 Sep 2026

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

Yahoo Finance Fri, 04 Sep 2026

DENTSPLY SIRONA (XRAY) Returns To Profit As Investors Weigh Its Valuation

DENTSPLY SIRONA (XRAY) shares are in focus after the company reported second quarter 2026 results that returned the business to profitability while net sales declined 4.1% year over year. The latest results and upcoming appearance at the Ba…

Yahoo Finance Fri, 04 Sep 2026

Dentsply Sirona (XRAY) Stock May Still Trade At A Discount

DENTSPLY SIRONA stock has had a difficult run over the past few years, yet on broad valuation checks it now screens as one of the cheaper options in its peer group. The share price history and the current multiples are sending very differen…

Yahoo Finance Fri, 04 Sep 2026

Does XRAY’s Profit Recovery and Reaffirmed 2026 Outlook Shift the Dentsply Sirona Thesis?

Dentsply Sirona recently reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and also confirmed it will present at the Baird 2026…

Yahoo Finance hu, 03 Sep 2026

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is sch…

Yahoo Finance hu, 03 Sep 2026

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year ea…

XRAY — Frequently Asked Questions

What is the current share price of DENTSPLY SIRONA Inc. (XRAY)?

As of 2026-09-16 18:39 PDT, DENTSPLY SIRONA Inc. (XRAY) trades at $10.14 on NasdaqGS. Its 52-week range is $9.64 to $14.68.

What is the market capitalisation of XRAY?

DENTSPLY SIRONA Inc. (XRAY) has a market capitalisation of $2.03B on NasdaqGS.

What is the P/E ratio of XRAY?

XRAY trades at a trailing price-to-earnings (P/E) ratio of -3.50. The industry average P/E is 24.25. Its price-to-book (P/B) ratio is 1.84.

Does XRAY pay a dividend?

DENTSPLY SIRONA Inc. (XRAY) currently offers a dividend yield of 5.04%.

What is the return on equity (ROE) of XRAY?

XRAY has a return on equity (ROE) of -37.67%. Its return on capital employed (ROCE) is 6.17%.

Is XRAY a good stock to buy?

This page provides a data-driven analysis of DENTSPLY SIRONA Inc. (XRAY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space